Abstract Details

Title Impact of Early-stage Relapsing Remitting Multiple Sclerosis on Quality of Life

Topic Multiple Sclerosis

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-006

Objective

The study’s aim was to assess the impact of early-stage relapsing remitting multiple sclerosis (RRMS) on health-related quality of life (HRQoL).

Background Number of relapses, disability progression, and symptomatology can reduce RRMS patients’ HRQoL. However, limited information is available in early-stage patients.

Design/Methods A multicentre, non-interventional study was conducted. Adult patients with RRMS diagnosis, disease duration ≤3 years, and Expanded Disability Status Scale (EDSS) score between 0-5.5 were included. The 29-item Multiple Sclerosis Impact Scale (MSIS-29), SymptoMScreen (SyMS), 8-item Stigma Scale for Chronic Illness (SSCI-8), Hospital Anxiety and Depression Scale (HADS), Modified Fatigue Impact Scale (MFIS), 23-item Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ-23), and EDSS were used to assess HRQoL, symptom severity, perception of stigma, depression and anxiety, fatigue, workplace barriers, and disability, respectively. Outcome measures associations were analyzed using Pearson correlation.

Results

A total of 189 patients were included (mean age: 36.1±9.4 years, 71.4% female, mean disease duration: 1.4±0.8 years, median EDSS: 1.0 [IQR: 0-2]).

Mean physical and psychological MSIS-29 sub-scores were 29.2±11.3 and 17.2±6.6, respectively. Mean SyMS score was highest for fatigue (1.6±1.4). Stigma prevalence was 56.6% (n=107/189) and 24.9% (n=47/189) of patients were probable anxiety cases. Physical and psychological MSIS-29 showed a significant correlation between them (rho=0.702, p<0.0001). Physical MSIS-29 subscale showed strong significant correlations with symptom severity, fatigue, and workplace barriers (rho=0.822, 0.778, 0.725, respectively, all p<0.0001). Psychological MSIS-29 subscale showed strong significant correlations with anxiety, depression, symptom severity, workplace barriers, and fatigue (rho=0.817, 0.791, 0.759, 0.722, 0.716, respectively, all p<0.0001). Symptom severity and workplace barriers were both strongly correlated with fatigue (rho=0.800, 0.774, respectively, p<0.0001). Stigma was moderately correlated with both MSIS-29 subscales (p<0.0001).

Conclusions RRMS can affect patients’ HRQoL even in early stages of the disease. Evaluating symptomatology impact at disease onset can help clinicians discerning when to apply early interventions, improving patient care and patients’ well-being.

Authors/Disclosures
Tamara Castillo-Trivino, MD, MAS, FAAN (Donostia University Hospital) PRESENTER	Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Castillo-Trivino has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol-Myers Squibb. The institution of Dr. Castillo-Trivino has received research support from Basque Government.
Rocío Gómez, Other (Roche Farma S.A.)	Ms. Gómez has received personal compensation for serving as an employee of Roche Farma Spain, Medical Department.
	No disclosure on file
Jesus Manuel Martin Martinez	Jesus Manuel Martin Martinez has nothing to disclose.
Javier Sotoca Fernandez	Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Javier Sotoca Fernandez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
Ana M. Alonso Torres, MD	Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alonso Torres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Ana Belen Caminero Rodriguez, MD (C/ Fuentes Claras #1)	Dr. Caminero Rodriguez has nothing to disclose.
Laura Borrega Canelo	Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BRISTOL. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NOVARTIS. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BRISTOL. Laura Borrega Canelo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Laura Borrega Canelo has received research support from BRISTOL.
Jose Luis Sanchez Menoyo, MD (Neurologia - Hospital Galdakao-Usansolo)	Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Sanchez Menoyo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Francisco Barrero-Hernandez	No disclosure on file
Carmen Calles, MD (Grupo 7 Viajes)	Dr. Calles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi, Biogen, Roche, Teva, Novartis, Merck. Dr. Calles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Teva, Biogen, Roche, Novartis, Merck.
Luis Brieva Ruiz, MD (Hospital Arnau Vilanova)	Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for All comercial companies interested in Multiple Sclerosis. Dr. Brieva Ruiz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Al comercial companies in Multiple Sclerosis. The institution of Dr. Brieva Ruiz has received research support from Carlos III Institut. Madrid. Spain..
Rosario Blasco Quilez (Hospital Puerta De Hierro)	Rosario Blasco Quilez has nothing to disclose.
Julio Dotor Garcia-Soto	JULIO DOTOR GARCÍA-SOTO has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck . JULIO DOTOR GARCÍA-SOTO has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck, Biogen, Sanofi-Genzyme, Almirall, Teva, UCB, Novartis.
Maria Campo Amigo	Maria Campo Amigo has nothing to disclose.
Laura Navarro	Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen idec. Laura Navarro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme.
Eduardo Aguera Morales, MD, PhD (As. ENINDE V14776132)	Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Aguera Morales has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis .
	No disclosure on file
Olga Carmona	Olga Carmona has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Olga Carmona has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NEURAXPHARME. Olga Carmona has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI. Olga Carmona has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for SANOFI. Olga Carmona has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NEURAXPHARM.
	No disclosure on file
	No disclosure on file
Mariona Hervas Pujol	Mariona Hervas Pujol has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi, Merk, Bayer, Biogen, Almirall.
	No disclosure on file
Jorge Maurino	Jorge Maurino has received personal compensation for serving as an employee of Roche Pharma Spain, Medical Department.
	No disclosure on file

��ɫ��

��ɫ��